X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (715) 715
Publication (87) 87
Book Review (43) 43
Conference Proceeding (5) 5
Dissertation (3) 3
Book Chapter (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (608) 608
humans (581) 581
cytochrome p-450 cyp2c8 (405) 405
pharmacology & pharmacy (374) 374
cyp2c8 (308) 308
female (228) 228
male (222) 222
aryl hydrocarbon hydroxylases - genetics (201) 201
metabolism (201) 201
pharmacokinetics (194) 194
aryl hydrocarbon hydroxylases - metabolism (173) 173
cytochrome p-450 cyp2c9 (171) 171
cytochrome p-450 enzyme system - metabolism (155) 155
adult (145) 145
cytochrome p-450 (142) 142
middle aged (125) 125
drug interactions (121) 121
human liver-microsomes (118) 118
paclitaxel (118) 118
pharmacogenetics (114) 114
genotype (113) 113
in-vitro (113) 113
microsomes, liver - enzymology (107) 107
aryl hydrocarbon hydroxylases (100) 100
cytochrome p-450 enzyme system - genetics (92) 92
cytochrome p450 (92) 92
animals (90) 90
steroid 16-alpha-hydroxylase (90) 90
plasma-concentrations (87) 87
microsomes, liver - metabolism (86) 86
cyp3a4 (79) 79
aged (76) 76
aryl hydrocarbon hydroxylases - antagonists & inhibitors (76) 76
cytochrome p-450 cyp3a (72) 72
gemfibrozil (72) 72
kinetics (72) 72
polymorphism, genetic (72) 72
polymorphism (71) 71
microsomes, liver - drug effects (70) 70
enzymes (69) 69
expression (67) 67
genetic polymorphisms (67) 67
cytochrome p-450 cyp2c8 - metabolism (66) 66
polymorphisms (65) 65
cytochrome p-450 cyp2c8 - genetics (64) 64
toxicology (64) 64
physiological aspects (62) 62
cyp2c9 (61) 61
area under curve (60) 60
biochemistry & molecular biology (60) 60
biotransformation (60) 60
polymorphism, single nucleotide (59) 59
analysis (58) 58
inhibition (58) 58
research (58) 58
hydroxylation (57) 57
cytochrome p-450 enzyme inhibitors (55) 55
genetic aspects (55) 55
hypoglycemic agents - pharmacokinetics (55) 55
enzyme inhibitors - pharmacology (52) 52
in vitro techniques (52) 52
alleles (51) 51
cytochrome p-450 cyp3a - metabolism (48) 48
drug-drug interactions (48) 48
cytochrome p-450 cyp2c19 (47) 47
drug metabolism (46) 46
repaglinide (46) 46
young adult (46) 46
cross-over studies (45) 45
identification (44) 44
recombinant proteins - metabolism (42) 42
cytochrome p4502c8 (41) 41
dose-response relationship, drug (41) 41
gene frequency (41) 41
metabolites (41) 41
pharmacology (41) 41
abridged index medicus (40) 40
cancer (40) 40
risk factors (40) 40
genetics & heredity (39) 39
substrate specificity (38) 38
adolescent (37) 37
oncology (37) 37
pharmacology/toxicology (37) 37
rosiglitazone (35) 35
liver (34) 34
liver - metabolism (34) 34
pharmacodynamics (34) 34
rats (34) 34
steroid hydroxylases - metabolism (34) 34
mixed function oxygenases - metabolism (33) 33
paclitaxel - pharmacokinetics (33) 33
biomedicine (32) 32
carbamates - pharmacokinetics (32) 32
cytochrome p-450 cyp3a - genetics (32) 32
drug-drug interaction (32) 32
epoxyeicosatrienoic acids (32) 32
liver - enzymology (32) 32
p-glycoprotein (32) 32
thiazolidinediones - pharmacokinetics (32) 32
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (705) 705
Japanese (9) 9
Spanish (4) 4
Chinese (2) 2
German (2) 2
Korean (2) 2
Croatian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


06/2012
3-Methylcholanthrene (MC) is a model polycyclic aromatic hydrocarbon that induces cytochrome P450 1A1 (CYP1A1) expression. This laboratory has shown previously... 
CYP2C8 | drug metabolism | 0419
Dissertation
11/2013
Background: The cytochrome P450 enzymes (CYP) play an important role in the metabolism of many therapeutic agents. The activities of different enzymes exhibit... 
CYP2C8 | CYP2B6 | polymorphism | allele frequency
Web Resource
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2017, Volume 83, Issue 12, pp. 2778 - 2788
AimsBased on in vitro data, there is evidence to suggest that cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite,... 
pharmacokinetics | rifampicin | selexipag | CYP2C8 | drug interactions | gemfibrozil | PULMONARY ARTERIAL-HYPERTENSION | TREPROSTINIL | REPAGLINIDE | CLOPIDOGREL | CONCISE GUIDE | PHARMACOLOGY | TOLERABILITY | PROSTACYCLIN RECEPTOR AGONIST | PHARMACOLOGY & PHARMACY | INHIBITOR | Prodrugs - administration & dosage | Activation, Metabolic | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Acetates - adverse effects | Acetates - blood | Area Under Curve | Humans | Middle Aged | Pyrazines - administration & dosage | Antihypertensive Agents - administration & dosage | Half-Life | Male | Metabolic Clearance Rate | Gemfibrozil - adverse effects | Healthy Volunteers | Acetamides - blood | Young Adult | Rifampin - adverse effects | Drug Interactions | Acetamides - adverse effects | Cytochrome P-450 CYP2C8 Inducers - adverse effects | Adult | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Gemfibrozil - administration & dosage | Cytochrome P-450 CYP2C8 Inducers - administration & dosage | Acetamides - pharmacokinetics | Risk Assessment | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Prodrugs - adverse effects | Acetates - administration & dosage | Prodrugs - pharmacokinetics | Pyrazines - pharmacokinetics | Adolescent | Pyrazines - adverse effects | Pyrazines - blood | Germany | Acetamides - administration & dosage | Acetates - pharmacokinetics | Metabolites | Gemfibrozil | Cytochrome P-450 | Nausea | Drug therapy, Combination | Rifampin | Fibric acids | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 06/2019, Volume 105, Issue 6, pp. 1295 - 1299
Clopidogrel perpetrates pharmacokinetic interactions primarily due to time--dependent inhibition (TDI) of cytochrome P450 (CYP) 2C8 by a circulating... 
PHARMACOLOGY & PHARMACY | METABOLITE | CYP2C8
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2016, Volume 81, Issue 2, pp. 313 - 315
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 2016, Volume 44, Issue 8, pp. 1364 - 1371
The glucose-lowering drug pioglitazone undergoes hepatic CYP2C8-mediated biotransformation to its main metabolites. The antiplatelet drug clopidogrel is... 
IN-VITRO | PHARMACOKINETICS | DEPENDENT INHIBITOR | SIMVASTATIN ACID | SLCO1B1 POLYMORPHISM | PHARMACOLOGY & PHARMACY | CERIVASTATIN | TRANSPORTING POLYPEPTIDE 1B1 | TYPE-2 DIABETES-MELLITUS | CYTOCHROME-P450 3A4 | DRUG-DRUG INTERACTIONS | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Area Under Curve | Humans | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Thiazolidinediones - administration & dosage | Thiazolidinediones - pharmacokinetics | Platelet Aggregation Inhibitors - blood | Young Adult | Hypoglycemic Agents - blood | Drug Interactions | Hypoglycemic Agents - administration & dosage | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Pharmacogenomic Variants | Ticlopidine - administration & dosage | Adult | Female | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Cytochrome P-450 CYP2C8 - metabolism | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - pharmacokinetics | Drug Administration Schedule | Risk Assessment | Administration, Oral | Genotype | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Thiazolidinediones - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Phenotype | Finland | Cytochrome P-450 CYP2C8 - genetics | Hypoglycemic Agents - adverse effects | Thiazolidinediones - blood | Ticlopidine - blood | Index Medicus
Journal Article
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 09/2018, Volume 46, Issue 9, pp. 1268 - 1276
Journal Article
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 09/2016, Volume 36, Issue 9, pp. 1919 - 1927
OBJECTIVE—Pathological ocular neovascularization is a major cause of blindness. Increased dietary intake of ω-3 long-chain polyunsaturated fatty acids (LCPUFA)... 
Diabetic retinopathy | Choroidal neovascularization | Arachidonic acid | Docosahexaenoic acid | CYP2C inhibitor | Neovascularization, Physiologic - drug effects | Humans | Retinopathy of Prematurity - genetics | Quinolines - pharmacology | Retinopathy of Prematurity - physiopathology | Fatty Acids, Omega-3 - pharmacology | Lasers | Hyperoxia - complications | Retinopathy of Prematurity - enzymology | Retinal Neovascularization - enzymology | Retinal Neovascularization - prevention & control | Retinal Neovascularization - genetics | Cytochrome P-450 CYP2C8 - metabolism | Aorta - enzymology | Disease Models, Animal | Cytochrome P-450 CYP2C8 Inhibitors - pharmacology | Fatty Acids, Omega-3 - metabolism | Tissue Culture Techniques | Aorta - drug effects | Mice, Inbred C57BL | Cells, Cultured | Choroidal Neovascularization - enzymology | Angiogenesis Inhibitors - pharmacology | Genotype | Mice, Transgenic | Choroidal Neovascularization - prevention & control | Choroidal Neovascularization - physiopathology | Phenotype | Animals | Retinopathy of Prematurity - prevention & control | Acetates - pharmacology | Cytochrome P-450 CYP2C8 - genetics | Retinal Neovascularization - physiopathology | Choroidal Neovascularization - genetics | Endothelial Cells - enzymology | Endothelial Cells - drug effects | Index Medicus | pathological angiogenesis | ω-3 LCPUFA
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 11, pp. 1748 - 1759
Genetic variations in CYP 2C (CYP2C) subfamily, CYP2C8, CYP2C9, and CYP2C19 contribute to interindividual variability in the metabolism of clinically used... 
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 8/2017, Volume 56, Issue 8, pp. 977 - 985
The aims of this study were to determine the effects of the CYP2C8*3 and *4 polymorphisms on imatinib metabolism and plasma imatinib concentrations in chronic... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | TYROSINE KINASE INHIBITORS | IN-VITRO | GENETIC POLYMORPHISMS | TRANSPORTER POLYMORPHISMS | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | CLINICAL PHARMACOKINETICS | N-DEMETHYLATION | CYP3A4 | P-GLYCOPROTEIN | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imatinib Mesylate - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Imatinib Mesylate - pharmacokinetics | Imatinib Mesylate - administration & dosage | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Cytochrome P-450 CYP2C8 - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Pharmacogenetics - methods | Cytochrome P-450 CYP2C8 - drug effects | Genotype | Protein Kinase Inhibitors - blood | Polymorphism, Genetic | Protein Kinase Inhibitors - administration & dosage | Imatinib Mesylate - blood | Receptor Protein-Tyrosine Kinases - genetics | Aged | Cytochrome P-450 CYP2C8 - genetics | Clinical Trials, Phase II as Topic | Protein Kinase Inhibitors - metabolism | Care and treatment | Cancer patients | Chronic myeloid leukemia | Research | Cytochrome | Studies | Plasma | Genotype & phenotype | Enzymes | Ratios | Metabolites | Leukemia | Metabolism | Patients | Drug dosages | Index Medicus
Journal Article
Journal Article